Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 29;8(6):e2897. doi: 10.1038/cddis.2017.288

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Knockdown of KDM2B attenuates tumor growth in vivo. (a) Plot demonstrating in vitro bioluminescence of shControl and shKDM2B cells transduced with Fluc-mCh constructs. (b) Long-term growth dynamic of shControl and shKDM2B cells were assessed by real-time cell analyzer for 202 h (n=6 wells for each group). (c) shControl-Fluc-mCh and shKDM2B-Fluc-mCh cells were subcutaneously implanted into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice and assessed for tumor growth for 30 days. Representative images of bilateral tumors of same mice from days 1, 14 and 22 displaying normalized bioluminescent efficiencies acquired (blue to red indicates lower to higher radiance as photons/s/cm²/steradian). (d) Tumor growth was measured by bioluminescent radiance on five time points for 30 days. Data were normalized to day 1 signal of each group (n=7 tumors per group). (e) Representative histology and immunofluorescence sections of tumors stained with H&E, anti-VEGF and annexin-V. (f) Number of blood vessels per 18 mm² are counted and plotted (n=3 fields per tumors)